Myasthenia gravis is a well-treatable disease, in which a prompt diagnosis and an adequate management can achieve satisfactory control of symptoms in the great majority of patients. Improved knowledge of the disease pathogenesis has led to recognition of patient subgroups, according to associated antibodies, age at onset and thymus pathology, and to a more personalized treatment. When myasthenia gravis is suspected on clinical grounds, diagnostic confirmation relies mainly on the detection of specific antibodies. Neurophysiological studies and, to a lesser extent, clinical response to cholinesterase inhibitors support the diagnosis in seronegative patients. In these cases, the differentiation from congenital myasthenia can be challenging. Treatment planning must consider weakness extension and severity, disease subtype, thymus pathology, together with patient characteristics and comorbidities. Since most subjects with myasthenia gravis require long-term immunosuppressive therapy, surveillance of expected and potential adverse events is critical. For patients refractory to conventional immunosuppression, the use of biologic agents is highly promising. These recommendations are addressed to non-experts on neuromuscular transmission disorders. The diagnostic procedures and therapeutic approaches hereafter described are largely accessible in Italy.
Epidemiologic and pathogenic aspects
Myasthenia gravis (MG) is the most frequent disorder of the NMT with a prevalence approaching 150/million [1] . IgG antibodies (Abs) against proteins expressed at the neuromuscular junction cause acetylcholine receptor (AChR) loss and postsynaptic dysfunction [2] .
Anti-AChR Abs are detected in approximately 85% of MG patients and act through three mechanisms: (1) complementmediated destruction of postsynaptic membrane; (2) increased AChR degradation through formation of antigen-Ab complexes that are internalized and destroyed inside the muscle fiber; (3) block of the ACh binding site [2] . MG with antiAChR Abs (AChR-MG) is associated with thymus follicular hyperplasia or thymoma both contributing in the disease pathogenesis [3] . According to age at presentation, gender bias, and thymus pathology, generalized AChR-MG is subdivided in early-onset, late-onset (age of onset ≥ 50 years), and thymoma-associated disease [2] . Early-onset AChR-MG is highly prevalent in females and strongly associated with thymus follicular hyperplasia, which is thought to be the site of sensitization against the AChR and a relevant source of specific Abs [3] . On the other hand, male predominance characterizes the late-onset subgroup; only minor inflammatory changes can be detected in thymus specimens from these subjects. AChR-MG is associated with thymoma in 10-15% of patients, with no gender bias and a peak age at onset around 50 years. A defective intra-tumorous thymocyte selection with the export of autoreactive T lymphocytes is thought to be responsible for MG development in these patients [3] .
Around 5-8% of patients have Abs to the muscle-specific tyrosine-kinase (MuSK). MuSK is activated by neural agrin through its co-receptor, the lipoprotein-related receptor 4 (LRP4). MuSK activation triggers an intracellular pathway leading to AChR clustering [4] . The main effect of antiMuSK Abs is a block of MuSK-LRP4 binding [5] . MuSK-MG has a striking prevalence in women with a peak age of onset in the fourth decade [6] .
Abs to LRP4 and agrin have been reported in some antiAChR/MuSK negative cases [2] . This still leaves a proportion of patients who are seronegative, i.e., without detectable Abs.
Clinical aspects
The clinical hallmark of MG is fluctuating muscle weakness that worsens with exertion and improves with rest. Clinical presentation is typical in most cases with broad variability in symptom severity.
Weakness of extrinsic ocular muscles (EOM) is responsible for ptosis and binocular diplopia. Ptosis is generally asymmetrical and may be alternating. Diplopia may be due to paresis of a single eye muscle, but multiple pareses are common.
Although ocular symptoms are very frequent at presentation, only in 15-20% of patients MG remains confined to EOM, as generally within 2 years from onset, weakness spreads to other muscle groups [7] .
Reduced strength of the orbicularis oculi muscle is responsible for weak eyelid closure. Weakness of lower facial muscles causes difficulty in blowing out cheeks and accounts for a characteristic vertical smile. Fatigability of the masseter results in progressive difficulty in chewing through the meal. BBulbar^symptoms are related to muscles innervated by motor-neurons in the medulla oblongata. Dysphagia is more relevant for liquids and hot food, and when severe, requires feeding through a nasogastric tube. Dysarthria can be apparent on prolonged talking, but speech may become unintelligible in severely affected cases. Tongue weakness contributes to speaking and eating difficulties and may evolve into a characteristic atrophy with one median and two lateral furrows (triple furrowed tongue). Weakness of neck extensors may cause a Bdropped head.Î n the limbs, proximal muscles are prevalently involved; weakness is bilateral, although its severity may be asymmetrical. Among distal muscles, finger extensors are more commonly affected; weakness of foot extensors occurs rarely. Reduced strength of pelvic floor muscles in MG women and of the external urethral sphincter in men can be responsible for urinary stress incontinence [7] .
Respiratory failure (myasthenic crisis) occurs in 15-20% of patients, more frequently in the first 2 years from onset [8, 9] . Ventilation failure is caused by weakness of the diaphragm and intercostal muscles together with upper airway obstruction by bronchial secretions and saliva aspiration. Crises are most often precipitated by respiratory infections. Other potential triggers are surgery, sedation, drugs interfering with NMT (see Table 1 ), withdrawal/overmedication of cholinesterase inhibitors, initiation of steroid treatment [8] .
MuSK-MG is characterized by predominant involvement of bulbar and axial muscles, with dysarthria, dysphagia, weakness of facial and neck muscles, and frequent respiratory crises; ocular symptoms are mild and often transient; limb muscles can be totally spared [6] .
Patients with anti-LRP4 Abs are mostly affected by mild generalized or ocular MG [13] .
MG scoring measures
The Osserman classification has been applied for many years [14] ; since 2000, the MG Foundation of America (MGFA) scale has been mostly used in clinical practice [15] . These classifications distinguish ocular from generalized myasthenia, and, in the latter, differentiate mild, moderate, and severe forms. They describe a patient's status at a certain point of his/her disease, do not quantify [15] . Other quantitative systems, such as the MG composite [16] , the manual muscle test for MG [17] , and the Besta Neurological Institute MG scale [18] , are available. Because of respiratory depression, they should be used with caution.
Radiographic contrast
Iodinate contrast As it may worsen myasthenic weakness, its administration should be avoided in patients with uncontrolled disease.
Muscle relaxants Dantrolene Neuromuscular transmission block Baclofen

Thiocolchicoside
Anticholinergic drugs
Trihexyphenidyl Neuromuscular transmission block Hyoscine
Otilonium
Miscellaneous drugs
Botulinum toxin Weakness in the region of local injection Amantadine Possible weakness after administration
Bold entries are associated with more common or more severe adverse event. Italics are associated with less common or less severe adverse events
Clinicians may choose among these systems provided they are consistent during patient follow-up. MG activities of daily living (MG-ADL) is a patientreported assessment of the disease impact on daily activities [19] . Other quality of life (QOL) measures, including the Italian versions of SF-36 [20] and MG-QOL15 [21] , are available. The use of patient-oriented measures in clinical practice is recommended.
Diagnosis
MG is easily suspected in patients presenting with a typical pattern of fatigable muscle weakness. As symptoms and signs may be evident only after exertion, maneuvers that fatiguespecific muscle groups can be useful. Facial, ocular, oropharyngeal, axial, and limb muscles should be tested. Tendon reflexes are normal; pain and autonomic signs are absent.
The clinical diagnosis of MG is confirmed by electromyography (EMG) studies, pharmacologic testing, and serum Ab assay. Positive results on EMG confirm a postsynaptic defect of the NMT, the clinical response to cholinesterase inhibitors (ChE-Is) supports MG diagnosis, and detection of specific Abs confirms MG and identify Ab-related subgroups. In patients with neither AChR nor MuSK Abs on standard assay, EMG confirmation is crucial.
EMG studies
Repetitive nerve stimulation
Repetitive nerve stimulation (RNS) protocol includes 1-2 baseline trains of supramaximal nerve stimuli at low frequency (2-5 Hz) followed by isometric contraction of the muscle for 15-20 s, and, within 10 s after muscle contraction, by another train of low-frequency stimuli, which aims at recording facilitation. Three trains of stimuli are then given at 1, 3, and 5 min after muscle contraction to document postactivation exhaustion followed by gradual recovery.
The compound muscle action potential (CMAP) amplitude depends on the number of activated muscle fibers. In MG, the first stimulus evokes a normal CMAP unless weakness is very severe. RNS at low frequency is typically associated with a CMAP decrement greater than 10% between the first and fourth response, followed by a partial decrement repair producing a BU-shaped^curve [22] . Such Bdecremental response^is the neurophysiological equivalent of muscle fatigability.
In MG, post-activation facilitation (i.e., CMAP amplitude increment after a brief voluntary contraction) is between 10 and 25% and rarely reaches 50%. Post-activation exhaustion, i.e., a further CMAP decrement, is usually seen 1-3 min after muscle contraction [22] .
RNS sensitivity depends on testing weak muscles and is increased by muscle warming at 32-34°C. Cholinesterase inhibitors (ChE-Is) should be withdrawn, when possible, 12 h before testing.
RNS of hand muscles is well tolerated. Examination of proximal muscles increases diagnostic yield but is more painful and associated with movement artifacts. Stimulation of the accessory nerve is well tolerated and should be performed when RNS in distal muscles is negative [23] . Examination of cranial muscles (nasalis, orbicularis oculi, masseter) increases RNS sensitivity in patients with ocular symptoms and in MuSK-MG [24] .
A decremental response on low-rate RNS is present in other primary disorders of NMT and, less frequently, in amyotrophic lateral sclerosis (ALS) and radiculopathy. Most congenital myasthenic syndromes (CMSs) have the same pattern as MG on the above RNS/activation protocol. On the other hand, Lambert-Eaton myasthenic syndrome (LEMS) and botulism are characterized by low amplitude of the first CMAP, further CMAP decrement during low-rate RNS and CMAP amplitude restoration (potentiation) during high-rate RNS or immediately after a brief maximal muscle contraction [22] .
Single-fiber electromyography
Single-fiber electromyography (SF-EMG) measures the neuromuscular jitter, i.e., the latency variability in the depolarization of muscle fibers belonging to the same motor unit. In MG, the reduced EPP amplitude prolongs the time to reach the firing threshold (increased jitter) and muscle fiber AP can be blocked [22] .
SF-EMG is generally performed during voluntary muscle contraction. In non-cooperative patients (as in children), APs can be elicited by axon stimulation; in this case, jitter measures the interval variations between the stimulus and the AP of single muscle fibers. Jitter is expressed as mean consecutive difference of inter-potential intervals [25] . The extensor communis digitorum muscle is generally tested first; in case of negative results, the study is extended to facial muscles.
SF-EMG is the most sensitive test for MG diagnosis, and, when limb and facial muscles are examined, positive results are recorded in > 90% of cases [26, 27] . SF-EMG of cranial muscles has a high diagnostic yield in patients with ocular myasthenia [27] or MuSK-MG [6] . However, an increased jitter is not specific as, apart from other diseases of NMT, it can be found in neurogenic and myopathic conditions [27] .
Pharmacological testing
ChE-Is prolongs ACh half-life at the synaptic cleft and, in MG, improve NMT as ACh can repeatedly bind the remaining AChRs. A positive response to ChE-Is, as unequivocal clinical improvement, although not specific, strongly supports the diagnosis of MG.
Parenterally given short-acting agents, as edrophonium and neostigmine, are used for diagnostic purposes. Clinical response should be evaluated on symptomatic muscles and compared with that obtained from a previous placebo (or atropine) injection [7] .
In MG, the rate of positive responses to ChE-Is is around 90%. In patients with MuSK Abs, ChE-I injection is often ineffective, elicits cholinergic side effects, and may even induce clinical deterioration [6] .
A positive reaction to ChE-Is is observed in CMS and, to a lesser extent, in LEMS. False responses have been reported in ALS, Guillain-Barrè syndrome [28] , and in single patients with brainstem lesions [29] .
Antibody assays
Anti-AChR and -MuSK Abs are routinely tested by a radioimmunoprecipitation assay (RIPA). Quality controls for these assays have been promoted by the Italian Association of Neuroimmunology, and specific guidelines have been published [30] .
When MG is suspected on clinical ground, anti-AChR Abs are the first to be tested. Anti-MuSK should be assayed in all AChR-negative cases. As Abs can be undetectable at onset and become positive afterwards, negative results on RIPA should be confirmed in two subsequent assays, 6 months apart.
Anti-AChR and anti-MuSK are very specific, and, in practice, their detection in patients with congruous symptoms confirms the diagnosis. The diagnostic accuracy of anti-AChR RIPA ranges 97-99% [26] as positive results may rarely be found in ALS [31] and in association with thymoma (these patients are at risk of developing MG) [32] . Abs to MuSK have never been reported outside MG [33] .
In patients negative on standard RIPA, MG-specific Abs to AChR or MuSK expressed on cell membrane can be detected on cell-based assays (CBA), more commonly in children and in patients with mild disease [34, 35] . Anti-LRP4 and antiagrin Abs have been reported at different rates in dSN-MG [2, 13] . Commercial assays for these Abs are not available.
A diagnostic algorithm is shown in Fig. 1 .
Additional diagnosing testing
The ice-pack test can be helpful in patients with ptosis. It is performed by applying an iced pack across the eyelid for 2 min; ptosis modification is evaluated 5-10 s after ice removal. A palpebral fissure increase > 2 mm is considered a positive response [36] . The ice-pack test has a high negative predictable value (94%) [36] and is a useful bed-side test provided the final diagnosis is based on Ab assay and EMG studies. Abs to the intracellular muscle proteins, titin and ryanodine receptor (RyR), can be detected in AChR-MG, strongly associated with thymoma (anti-titin Abs in 95% and anti-RyR in 70% of thymoma patients) and to a lesser extent with lateonset disease. These Abs are useful markers of thymoma in early-onset AChR-MG [33] .
Upon MG diagnosis, all patients (especially those with AChR-MG) should undergo a radiological study of the mediastinum through computed tomography or magnetic resonance imaging.
Given MG high-rate association with thyroid disease, specific Abs and hormones should be tested. Screening for medical conditions, such as diabetes, arterial hypertension, osteoporosis, and active infections, which could complicate management, is recommended.
Differential diagnosis
In seronegative patients, MG must first be distinguished from other disorders of NMT. The differential diagnosis with CMS should be undertaken by referral centers [37] .
ALS with prevalent bulbar symptoms can be misdiagnosed as MG. Of note, in these patients, ChE-Is may induce mild improvement, RNS and SF-EMG can show NMT defect, and anti-AChR [33] and anti-LRP4 Abs can be detected [38] . However, EMG studies can clarify the diagnosis.
In patients with symmetrical ophthalmoparesis, a mitochondrial disorder should be considered. Miller-Fisher syndrome may be confused with MG when ataxia and pupillary changes are not evident; in these patients, SF-EMG often shows abnormal NMT [39] .
Treatment
Treatment is aimed at achieving satisfactory control of symptoms minimizing the risk for adverse events (AEs). This goal can be achieved through individualized therapeutic choices.
Symptomatic treatment
It is based on ChE-Is, with pyridostigmine (Mestinon®) being the agent for oral treatment in Italy.
The great majority of MG patients respond, to some extent, to Mestinon with inter-individual variability in tolerance. Treatment is started at 30 mg three to four times daily. If well tolerated, it can be increased to 60 mg (1 tablet) four times daily, and, when needed, up to 90 mg five times daily. Higher doses are associated with little benefit and AEs. For infants and children, dosage is based on body weight starting at 1 mg/kg. Pyridostigmine affect peaks 1-1.5 h after ingestion and wears off in 3.5-4 h [40] . A sustained-release preparation (Mestinon-Timespan® 180 mg) can be prescribed at bedtime for patients symptomatic early in the morning or during the night. AEs mostly consist of gut hyperactivity, diarrhea, hyperhidrosis, and fasciculations and can usually be controlled by dose adjusting. Cholinergic crisis with severe clinical deterioration is currently a rare event, as early immunosuppression has reduced the need for high doses of symptomatic therapy. In MuSK-MG, ChE-Is should not be used as generally ineffective and associated with AEs [6] .
Immunosuppressive therapy
Immunosuppression is used in all patients with disabling symptoms not adequately controlled with ChE-Is. Steroids are generally first-line therapy because of their rapid effect; steroidsparing agents are commonly associated in long-term treatment.
Steroids
Oral prednisone is generally used because of its strong immunosuppressive activity and relatively short half-life [40] . The initial dose in generalized MG is 0.75-1 mg/kg/day. Clinical response is usually observed within 2-3 weeks and maximal improvement within 2-3 months. Treatment can also be started at low doses (5-10 mg) with an increasing schedule (i.e., 5 mg every 5-7 days) [41, 42] .
MG worsening can occur in the initial phase of steroid administration [7, 41, 42] . As this Bearly deterioration^can be severe and progress to respiratory failure, patients with bulbar weakness should be hospitalized for treatment initiation and carefully monitored; plasma exchange or intravenous immunoglobulin (IVIg) is recommended for severely affected patients.
Patients with ocular or mild symptoms can start prednisone as outpatients, at lower doses [43] . Once stable improvement is achieved, treatment is usually shifted to alternate-day administration and gradually tapered to the minimum effective dose [40] [41] [42] .
Steroid AEs include osteoporosis, cataract, diabetes, hypertension, glaucoma, weight gain, and skin disorders. Adequate prevention (salt and sugar dietary restriction, proton pump inhibitors) and treatment (i.e., diphosphonates for osteoporosis) as well as specialist monitoring should be planned.
Immunosuppressants
All these agents have a longer latency of effect than prednisone. Immunosuppressants are mostly used as Bsteroid-sparing agents,^can replace steroids in long-term treatment, and can be used in monotherapy in patients with mild nonprogressive MG.
Before treatment, active infections, particularly viral hepatitis and tuberculosis, must be excluded.
Azathioprine is the first-choice immunosuppressant in MG. It proved effective as steroid-sparing agent in a randomized controlled trial (RCT) [44] . Treatment is started at 50 mg (1 tablet) once a day, increasing of 50 mg/week up to 2.5 mg/kg/ day. This dosage is maintained for 10-12 months, then is gradually tapered to 1 mg/kg daily [42] . Few patients may be intolerant of azathioprine developing a flu-like syndrome with fever, malaise, and vomiting in the first 2 weeks of treatment.
Liver function and complete blood count should be evaluated each week for 1 month, then every 2 months. Increased serum levels of liver enzymes usually normalize with dose tapering; persistent hepatic or pancreatic dysfunction requires azathioprine withdrawal.
Azathioprine should be reduced when white blood count (WBC) falls below 4 × 10 9 /l and must be withheld if WBC reaches 3 × 10 9 /l. Mild macrocytic anemia is a common AE [42] .
Individuals carrying nonfunctional alleles of thiopurine Smethyltransferase (TPMT), the enzyme that inactivates azathioprine, may experience severe myelosuppression when receiving azathioprine at conventional doses [45] . TPMT functional and genetic assays have not yet entered the routine practice.
Although two RCTs (severely limited by the protocol design) did not demonstrate additional benefit of mycophenolate mofetil (MMF) over prednisone [46] , several studies support MMF efficacy in MG patients, including those with refractory disease [47] . MMF is initiated at 500 mg/day with an escalating regimen up to 1.5-2 g/daily. Improvement has been reported after 2-3 months, with maximum benefit after 6-18 months. AEs include gastrointestinal discomfort, leucopenia, and infection; liver toxicity is less common than with azathioprine [48] .
Cyclosporine effectiveness in MG has been proved in a RCT [49] , not followed, however, by further reports on large series. Treatment is started at 4-5 mg/kg/day in two divided doses. Improvement is usually evident after 2 months, with a peak after 3-4 months. In chronic treatment, dosages of 2-3 mg/kg/day are often adequate.
Periodic controls of WBC and liver enzymes are necessary. Renal function should be monitored, titrating cyclosporine to keep creatinine level < 150% of pretreatment value [42] . As chronic administration entails the risk of severe AEs (nephrotoxicity, hypertension, skin malignancy, tremor, hypertrichosis, and gingival hypertrophy), cyclosporine is usually considered after failure of other agents.
Tacrolimus proved effective in retrospective studies and two RCTs [50] . A dose of 3 mg/day is generally accepted for MG treatment. Its safety profile is like that of cyclosporine, but it was shown to be less nephrotoxic at low doses (0.1 mg/kg/day) [51] .
Measuring cyclosporine and tacrolimus concentrations in blood is helpful, especially in the early stages of treatment.
RCTs investigating the steroid-sparing effect of methotrexate yielded conflicting results [52, 53] . This agent is not expensive and generally well tolerated but has had limited use in MG so far.
Oral treatment with cyclophosphamide is limited by severe AEs as alopecia, leukopenia, nausea, vomiting, hemorrhagic cystitis, sterility, increased risk for infection and malignancy, and is restricted to patients who have failed less toxic agents including rituximab [54] . Pulse intravenous treatment (500 mg/m 2 /monthly) is better tolerated and proved effective in refractory disease [55] .
Rituximab (Mabthera®) is an anti-CD20 monoclonal Ab which depletes circulating B cells. From retrospective observations and meta-analyses, rituximab appears to be effective in all forms of MG, especially in MuSK-MG [56, 57] . The results of a RCT in AChR-MG [ClinicalTrials.gov Identifier: NCT02110706] have not yet been published. Rituximab is predominantly used in patients refractory to conventional immunosuppression [54] , with two regimens: 375 mg/m 2 / week for four consecutive weeks and 1000 mg on day 1 and day 15. Most patients need more than one treatment cycle. In the absence of an established protocol, the decision to repeat rituximab should be based on clinical observation and on circulating B cell subpopulations. Rituximab is well tolerated with a low rate of severe AEs [57] . Progressive multifocal leukoencephalopathy has been reported in two MG patients previously treated with other immunosuppressants [56, 58] .
A recent RCT showed no significant benefit of belimumab, a mAb targeting the B cell activating factor (BAFF), in generalized AChR-MG [59] .
Eculizumab (Soliris®) binds to the protein C5 preventing complement activation. This agent has been approved for refractory AChR-MG, in view of the results a RCT mostly favoring eculizumab over placebo, in association with conventional immunosuppression [60] .
Short-term treatments
Plasma exchange and IVIg have a rapid albeit short-lived effect, and additional immunosuppression is usually needed. Plasma-exchange standard protocol consists of 3-6 exchanges of 1-1.5 plasma volumes on alternate days; IVIg is usually administered at 1-2 g/kg over 2-5 days. They are mainly used in treating disease exacerbations, in preventing MG deterioration at the start of steroid therapy and in preparation for surgery in selected cases. IVIg can be used as periodic treatment in patients intolerant of immunosuppressants [40, 54] .
Plasma exchange and IVIg were found to have comparable efficacy in the treatment of respiratory crisis [61] and moderate to severe MG [62] . Plasma-exchange AEs are mainly related to central venous catheters; IVIg administration can be complicated by allergic reaction, hemolysis, and thrombosis. The choice between these options is based on patient's comorbidities, procedure's risks, and medical facilities. In patients with life-threatening symptoms, plasma exchange is preferred because of its more rapid effect, while for outpatients, IVIg is more suitable [63] . Semi-selective immunoadsorption, which removes IgG leaving other plasma components unaltered, represents a valuable alternative in patients requiring intensive plasmaexchange protocols [64] .
Subcutaneous IgG may be a practical option in chronic management of MG. It proved effective and well tolerated in uncontrolled observations [65] .
Thymectomy
The rational for therapeutic thymectomy, i.e., thymectomy in non-thymoma patients to improve the disease course, relies on the pathogenic role of the thymus in MG. Its efficacy in generalized AChR-MG was assessed in a RCT comparing transsternal thymectomy plus prednisone with prednisone alone. Thymectomy proved effective in primary end-points (the average QMG score and prednisone requirement were significantly lower in the thymectomy group) as well as in several secondary outcomes [66] , although the benefit of thymectomy in patients older than 50 years of age remains undetermined [66] . Less invasive surgical approaches have been applied with increasing frequency. In Italy, considerable experience has been reached with video-assisted [67, 68] and robotic thymectomy [69] , which proved effective and safe in MG patients. The indication for thymectomy in ocular MG is controversial. There is no evidence of a pathogenic link between the thymus and MG with Abs other than anti-AChR [3] .
Radiologic evidence of a thymoma is an obvious indication to surgery. As additional treatment may be required, patients with thymoma should be managed by a multidisciplinary team. Even in thymoma patients, thymectomy should never be an emergency treatment but should be performed once a stable control of MG has been achieved.
Treatment flow charts are summarized in Figs. 2, 3 , and 4. Medications with contraindications in MG are listed in Table 1 .
MG treatment in pregnancy
Pyridostigmine is safe during pregnancy and lactation [54] . Prednisone is the immunosuppressant of choice during pregnancy [54] but should be avoided during lactation for daily doses > 10 mg [70] . Azathioprine and cyclosporine do not increase the risk for teratogenicity, whereas MMF, methotrexate, and cyclophosphamide must be avoided before conception (both in female and male patients) and during pregnancy [54, 71] . Plasma exchange and IVIg can be used weighing maternal/fetal risks [54] . Rituximab administration temporarily depletes B cell in the child [72] .
In the management of eclampsia, injectable magnesium should be avoided or, at least, serum magnesium levels should be monitored (concentrations ranging 3.5-7 mEq/l are considered safe) [73] . Methyldopa and hydralazine should be preferred in treating hypertension; phenytoin and levetiracetam are relatively safe in seizure prevention and treatment [74] .
Transient neonatal MG occurs in 15-20% of babies born to myasthenic mothers and may require symptomatic treatment as well as nutritional and respiratory assistance [54] .
Myasthenia gravis and vaccination
The main concern with vaccination in MG is that immunosuppression may prevent a sustained specific Ab response. Live attenuated vaccines are contraindicated, whereas inactivated vaccines, such as influenza and pneumococcal vaccines, are safe [75] . Annual flu vaccination is well tolerated and can prevent MG deterioration related to respiratory complications [76] .
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